10-Q: Helius Medical Q2 Loss Widens Amid Revenue Drop, Capital Raises

Helius Medical Technologies reported a significantly wider net loss in Q2 2025 due to decreased product sales, despite successful capital raises and regaining Nasdaq compliance.

Summary

• Net loss for the six months ended June 30, 2025, significantly widened to $13.7 million, compared to $4.1 million for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, decreased to $92 thousand from $317 thousand in the prior year, primarily due to reduced product sales in the U.S. and Canada.
• Product sales in the U.S. decreased from $146 thousand in H1 2024 to $26 thousand in H1 2025, while Canadian sales dropped from $149 thousand to $45 thousand.
• The company reported a gross loss of $125 thousand for the six months ended June 30, 2025, a decline from a gross profit of $76 thousand in the prior year.
• Operating expenses increased to $7.2 million for the six months ended June 30, 2025, up from $6.8 million in the same period last year.
• Cash and cash equivalents increased to $6.1 million as of June 30, 2025, from $1.1 million at December 31, 2024, largely due to financing activities.
• Working capital improved to $6.0 million as of June 30, 2025, from $1.3 million at December 31, 2024.
• The company successfully completed a public offering in June 2025, raising $9.1 million in gross proceeds, and a private placement in April 2025, generating $1.3 million in gross proceeds.
• Helius regained compliance with Nasdaq's Minimum Bid Price Requirement in June 2025 and the Stockholders Equity Requirement in July 2025, following reverse stock splits and capital raises.
• Preliminary analysis of the stroke registrational program studies showed the pivotal study met its primary endpoint, with FDA authorization submission targeted for Q3 2025 and approval by end of 2025 or early 2026.
• The company established Revelation Neuro, Inc. in March 2025 to develop an AI-powered brain-computer interface for neurorehabilitation.
• The exclusive distribution agreement with Health Tech Connex Inc. (HTC) in Canada was terminated in July 2025 due to a material breach by HTC, but a new product listing agreement with HealthPro, Canada's leading group purchasing organization, was secured in July 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant financial deterioration, including a widening net loss, substantial revenue decline, and a shift to gross loss. The 'going concern' warning is a major concern. However, successful capital raises, regaining Nasdaq compliance, positive preliminary stroke study results, and new strategic initiatives (Revelation Neuro, HealthPro agreement) provide some offsetting positive momentum and future potential, preventing a lower score.

Positives

• Successfully regained compliance with Nasdaq's Minimum Bid Price Requirement on June 3, 2025, and the Stockholders Equity Requirement on July 7, 2025.
• Completed a public offering in June 2025, raising $9.1 million in gross proceeds, and a private placement in April 2025, generating $1.3 million in gross proceeds.
• Generated $3.7 million in gross proceeds from a warrant exercise inducement offer in January 2025.
• Increased the at-the-market (ATM) offering program capacity to $25.0 million in July 2025, subsequently selling $5.0 million in net proceeds.
• Preliminary analysis of the stroke registrational program pivotal studies showed the primary endpoint was met, demonstrating statistically significant improvements in gait and/or balance deficit.
• On track to submit for FDA authorization for stroke in Q3 2025, with a plan to achieve authorization by the end of 2025 or early 2026.
• Secured first reimbursement payment from Anthem Blue Cross Blue Shield in March 2025, followed by approvals from United Healthcare in May 2025 and Aetna Healthcare in June 2025.
• Announced an additional authorized claim for payment from Anthem Multiplan and CignaHealth in June 2025.
• Secured a product listing agreement with HealthPro, Canada's leading group purchasing organization, in July 2025, enabling promotion to over 2,000 hospitals.
• Established Revelation Neuro, Inc. in March 2025 to pursue development of an AI-powered brain-computer interface for neurorehabilitation.

Negatives

• Net loss for the six months ended June 30, 2025, significantly widened to $13.7 million, compared to $4.1 million for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, decreased by 71% to $92 thousand from $317 thousand in the prior year.
• Product sales in the U.S. decreased by 82% to $26 thousand in H1 2025, and Canadian sales decreased by 70% to $45 thousand in H1 2025.
• Shifted from a gross profit of $76 thousand in H1 2024 to a gross loss of $125 thousand in H1 2025.
• Operating expenses increased to $7.2 million for the six months ended June 30, 2025, up from $6.8 million in the prior year.
• Net cash used in operating activities increased to $6.3 million for the six months ended June 30, 2025, from $5.9 million in the prior year.
• Accumulated deficit increased to $185.4 million as of June 30, 2025.
• The company's financial statements indicate substantial doubt about its ability to continue as a going concern within one year.
• Terminated the Exclusive Distribution Agreement with Health Tech Connex Inc. (HTC) in July 2025 due to a material breach by HTC, impacting Canadian sales.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year, requiring additional funding.
• The company may be negatively impacted by Nasdaq's expedited delisting rules for companies that have had one or more reverse stock splits with a cumulative ratio of one for 250 or more shares over the prior two-year period.
• Inability to raise sufficient additional capital could compel the company to reduce operations, sell assets, or cease/wind down operations.
• There is no assurance that the company will achieve profitable operations, or that profitability, if achieved, will be sustained.
• Global economic conditions, including supply chain disruptions, labor shortages, geopolitical conflicts, increased inflation, and high interest rates, could adversely affect the company's business, financial condition, results of operations, and liquidity.
• Broad commercial payer coverage and reimbursement for PoNS Therapy are anticipated to take at least 24 months from the HCPCS codes' effective date, creating uncertainty for future sales.

Future Outlook

The company intends to fund ongoing activities by utilizing current cash and cash equivalents, cash from PoNS device sales, and by raising additional capital through equity or debt financings. It expects to continue incurring operating losses and net cash outflows until sufficient revenue is generated. The company believes existing capital resources, including $5.0 million net proceeds from the July 2025 ATM, will fund operations into Q2 2026, but additional funding will be required thereafter, particularly for the planned clinical trial for stroke. The company is on track to submit for FDA authorization for stroke in Q3 2025, with a plan to achieve authorization by the end of 2025 or early 2026. Broad commercial payer coverage and reimbursement for PoNS Therapy are anticipated to take at least 24 months from the HCPCS codes' effective date.

Management Comments

• The company expects to continue to incur operating losses and net cash outflows until such time as it generates a level of revenue to support its cost structure.
• The company intends to fund ongoing activities by utilizing its current cash and cash equivalents on hand, cash received from the sale of its PoNS device in the U.S. and Canada and by raising additional capital through equity or debt financings.
• The company is on track to submit for FDA authorization for stroke in the third quarter of 2025, with the plan to achieve FDA authorization by the end of 2025 or early in 2026.
• The company intends to provide broad access and reimbursement for the PoNS Therapy over time through commercial insurers, anticipating it will take at least 24 months to obtain broad coverage and reimbursement from the date that the HCPCS codes became effective.

Industry Context

Helius Medical Technologies operates in the neurotechnology and medical device industry, focusing on non-implantable solutions for neurological conditions like multiple sclerosis and stroke. The company's PoNS device addresses gait and balance deficits, positioning it within the neurorehabilitation market. The industry is characterized by significant R&D investment, stringent regulatory approval processes (e.g., FDA authorization), and complex reimbursement landscapes, particularly for novel devices. The establishment of Revelation Neuro, Inc. to develop an AI-powered brain-computer interface reflects a broader industry trend towards integrating artificial intelligence and advanced computing into medical devices for personalized treatment. The company's efforts to secure HCPCS codes and reimbursement approvals from major payers like Anthem, United Healthcare, and Aetna highlight the critical importance of market access and payer adoption for commercial success in the medical device sector. The partnership with Lovell Government Services also indicates a strategy to penetrate federal healthcare systems, a common approach for medical device companies.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have a material adverse effect on its business, operating results, or financial condition.

Stakeholder Impact

• **Shareholders:** Experienced significant dilution and reverse stock splits, but also benefited from successful capital raises that improved liquidity and regained Nasdaq compliance. Continued risk of further dilution and stock price volatility remains.
• **Employees:** The 'going concern' uncertainty poses a risk to job security and future compensation, though recent capital raises provide some near-term stability.
• **Customers (Patients):** Potential for expanded access to PoNS Therapy through new reimbursement approvals and the HealthPro agreement in Canada. Positive stroke study results could lead to a new indication, benefiting more patients.
• **Partners (e.g., Maxim Group LLC, Roth Capital Partners, LLC, Lovell Government Services):** Continued engagement in financing and commercialization efforts, indicating ongoing business relationships and potential for future collaboration.
• **Health Tech Connex Inc. (HTC):** Termination of the exclusive distribution agreement due to material breach will negatively impact HTC's business relationship with Helius.

Next Steps

• Submit for FDA authorization for stroke in Q3 2025.
• Achieve FDA authorization for stroke by the end of 2025 or early 2026.
• Continue to pursue broad commercial insurance coverage for PoNS, anticipating at least 24 months for widespread adoption.
• Evaluate options with respect to potential strategic alternatives.
• Seek additional funding through equity or debt financings to continue operations beyond Q2 2026 and fund planned clinical trials for stroke.
• Actively promote PoNS to participating healthcare institutions across Canada through the new HealthPro product listing agreement.

Key Dates

Recommendation

Helius Medical Technologies faces significant financial challenges, including a widening net loss, substantial revenue decline, and a 'going concern' warning. These factors typically warrant a 'sell' recommendation. However, the company has demonstrated an ability to raise capital, successfully regained Nasdaq compliance, and reported positive preliminary results from its stroke study, which could lead to a new FDA-authorized indication. The new Canadian distribution agreement and the establishment of Revelation Neuro for AI-powered neurorehabilitation also offer future growth potential. Given this mix of severe financial distress alongside strategic progress and successful capital market activities, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to achieve profitability, secure broad reimbursement, and successfully commercialize its products, especially the stroke indication, before considering further investment.

Keywords

Helius Medical Technologies, HSDT, PoNS, neurotechnology, medical device, SEC filing, 10-Q, financial results, capital raise, Nasdaq compliance, stroke study, reimbursement, traumatic brain injury, multiple sclerosis, neuromodulation, going concern